Alexander Hardy
With over 30 years of experience, Alexander Hardy joins BioMarin as CEO, known for driving a 24% revenue growth at Genentech.
Hardy intends to apply his global product strategy and drug launch know-how to prioritize BioMarin’s R&D on promising assets, targeting higher revenue and improved margins.
While some criticize his strategy and arrogance, Hardy’s ex-colleagues at Genentech and Roche commend his integrity, CEO capabilities, and communication.
By submitting this form, you are agreeing to ManagementTrack’s Privacy Policy. You can choose to opt out of marketing or advertising emails using the ‘unsubscibe’ link included in our emails.
The best
The best
The best
Our investigative journalists interview the top former colleagues of the CEOs you care about.
Our former buysider analysts summarize the key strengths & weaknesses, past successes & failures, and ability to drive value going forward.
You get access to the actual anonymized transcripts and insights.